ASCO joined more than 120 other organizations in signing on to a letter urging Congress to introduce several improvements to ensure the continued success of efforts to implement the Medicare Access and CHIP Reauthorization Act.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
From June 8-12, ASCO’s delegates will participate in the American Medical Association’s (AMA) Annual Meeting of the House of Delegates (HOD). The AMA HOD is the principal policy-making body of AMA and meets twice a year to discuss pressing issues and establish association policies.
ASCO is seeking 10 oncology practices in urban centers in the U.S. with high proportions of African-American patients with breast cancer in 11 specific metropolitan areas to participate in its Quality Oncology Practice Initiative (QOPI®), QOPI® Certification, and Quality Training Program (QTP) offerings, with training and funding support provided.
As part of the collaboration that lead to the recent CDC clarification on its guideline on prescribing opioids to manage pain from certain conditions, leadership from the organizations came together to write an op-ed for ASCO Connection. That commentary from ASCO CEO Clifford A. Hudis, MD, FACP, FASCO; NCCN CEO Robert W. Carlson, MD; and ASH President Roy Silverstein, MD, fully outlines the groups’ concerns about how efforts to address the opioid crisis in the United States could inadvertently create a new crisis through the misguided application of well-intentioned clinical guidelines.
ASCO submitted comments to a U.S. House Energy & Commerce health subcommittee hearing entitled, “Improving Drug Pricing Transparency and Lowering Prices for American Consumers." The hearing focused on several bills aimed at increasing transparency around drug prices and lowering out-of-pocket costs for patients. ASCO’s comments offer the oncology community’s perspective on several of the bills discussed during the hearing and focus on improving access to affordable cancer care.
ASCO members are encouraged to use the ACT Network to tell their representatives in Congress to support the CLINICAL TREATMENT Act and protect patient access to clinical trials.
The American Society of Clinical Oncology (ASCO) applauds the Centers for Medicare & Medicaid Services (CMS) for listening to ASCO and other stakeholders by not finalizing a proposal that would have significantly impacted access to drugs within the Six Protected Classes.
Yesterday, the American Cancer Society’s Cancer Action Network (ACS CAN) released a new report entitled, Inadequate Coverage: An ACS CAN Examination of Short-Term Health Plans, which examined short-term plan coverage in six states: Florida, Illinois, Maine, Pennsylvania, Texas, and Wisconsin and outlined their impact on patients with cancer.
ASCO and the American Cancer Society Cancer Action Network (ACS CAN) hosted a reception on Capitol Hill for Members of Congress and their staff to underscore the two organizations’ shared policy priorities to improve research and cancer care delivery for patients and cancer survivors.
ASCO and Friends of Cancer Research have commended the U.S. Food and Drug Administration on four recently released draft guidance documents related to expanding clinical trial eligibility in a joint letter to Acting Commissioner Ned Sharpless, MD.
As part of ASCO’s State of Cancer Care in America™ initiative, the Journal of Oncology Practice published an infographic about opioids and cancer pain, which highlights the specific needs of patients with cancer and some of the hurdles they face in trying to access prescribed opioids to manage cancer-related pain.
ASCO submitted testimony to the U.S. House and Senate Appropriations Committees urging them to increase funding for the National Institutes of Health, National Cancer Institute, and Food and Drug Administration.
ASCO submitted its position statement on the impact that Pharmacy Benefit Managers (PBMs) have on cancer care to a U.S. Senate Finance Committee hearing, “Drug Pricing in America: A Prescription for Change, Part III.” PBM representatives testified in-person during the hearing, which was held as part of Congress’ ongoing efforts to address rising prescription drug costs in the United States. In its submission, ASCO reiterated the society’s concerns about the negative effects of certain PBM practices on patients and the cancer care system.
Today at the National Press Club, the American Society of Clinical Oncology (ASCO) announced a new task force aimed at reducing disparities and improving outcomes for patients and survivors of cancer who live in rural communities. The new “Rural Cancer Care Task Force” will identify opportunities to close the rural cancer care gap and implement strategies to improve rural cancer care in the United States.